Fioramonti J, Gaultier E, Toulouse M, Sanger G J, Bueno L
Neurogastroenterology & Nutrition Unit, INRA, Toulouse, France.
Neurogastroenterol Motil. 2003 Aug;15(4):363-9. doi: 10.1046/j.1365-2982.2003.00420.x.
The involvement of neurokinin receptors in visceral nociception is well documented. However, the role and localization of NK3 receptors is not clearly established. This study was designed to determine whether NK3 receptor antagonists crossing (talnetant) or not (SB-235375) the blood-brain barrier reduce the nociceptive response to colo-rectal distension (CRD) and whether NK3 antagonism reduces inflammation- or stress-induced hypersensitivity to rectal distension. Isobaric CRD and isovolumic rectal distensions were performed in rats equipped with intramuscular electrodes to record abdominal muscle contractions. In controls, CRD induced a pressure-related (15-60 mmHg) increase in the number of abdominal contractions. Both talnetant and SB-235375 [50 mg x kg-1, per oral (p.o.)], which had no effect on colo-rectal tone, reduced the number of contractions associated with CRDs from 30 to 60 mmHg. Three days after rectal instillation of TNBS, abdominal contractions were increased for rectal distension volume of 0.4 mL. This effect was not modified by talnetant (30 mg x kg-1, p.o.). Partial restraint stress increased abdominal contractions at all distension volumes (0-1.2 mL). Talnetant (10 mg kg-1, p.o.) abolished the increase observed for 0.8 and 1.2 mL. These results indicate that peripheral NK3 receptor antagonism reduced nociception associated with CRD and hypersensitivity induced by stress but not inflammation.
神经激肽受体参与内脏痛觉感受已有充分的文献记载。然而,NK3受体的作用和定位尚未明确确立。本研究旨在确定能够穿过血脑屏障的NK3受体拮抗剂(他奈坦)或不能穿过血脑屏障的NK3受体拮抗剂(SB - 235375)是否能降低对结直肠扩张(CRD)的痛觉反应,以及NK3拮抗作用是否能降低炎症或应激诱导的直肠扩张超敏反应。在配备肌内电极以记录腹部肌肉收缩的大鼠中进行等压CRD和等容直肠扩张。在对照组中,CRD导致腹部收缩次数随压力增加(15 - 60 mmHg)。他奈坦和SB - 235375[50 mg·kg⁻¹,口服(p.o.)]对结直肠张力均无影响,但可使与30至60 mmHg的CRD相关的收缩次数减少。在直肠内注入三硝基苯磺酸(TNBS)三天后,对于0.4 mL的直肠扩张体积,腹部收缩增加。他奈坦(30 mg·kg⁻¹,p.o.)并未改变这种效应。部分束缚应激在所有扩张体积(0 - 1.2 mL)下均增加腹部收缩。他奈坦(10 mg·kg⁻¹,p.o.)消除了0.8 mL和1.2 mL时观察到的收缩增加。这些结果表明,外周NK3受体拮抗作用可降低与CRD相关的痛觉感受以及应激诱导的超敏反应,但不能降低炎症诱导的超敏反应。